Abstract library

9 results for "Muller".
#16 Endoglin as indicator of metastatic neuroendocrine tumors of the pancreas
Introduction: Neuroendocrine tumors of the pancreas are rare, highly vascularized tumors. Endoglin, a Transforming Growth Factor-β co-receptor, is a marker for angiogenic endothelial cells. Angiogenesis is required for tumor progression and the development of metastases. Recently, endoglin expression was found to be a prognostic marker in pancreatic carcinomas. However, the role of endoglin in neuroendocrine pancreatic tumors has so far not been studied.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Patricia Kuiper
#986 Expression of the Truncated Somatostatin Receptor Variant Sstr5TMD4 in Medullary Thyroid Carcinoma
Introduction: Medullary thyroid carcinoma (MTC) is a rare tumor originating from thyroid parafollicular C cell. The only available treatment is surgical resection, which is not always feasible. Somatostatin and its receptors are expressed both in normal human thyroid C cells and in MTC, but their role has not been fully elucidated. The discovery of a truncated isoform of Sstr5, Sstr5TMD4, associated with increased invasiveness and aggressiveness in breast cancer, has opened new insight in the role of Sstr in cancers.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Daniela Molè
Keywords: MTC, SSTR5TMD4
#1546 O6-Methylguanine DNA Methyltransferase (MGMT) Expression by Immunochemistry May Help Predict Response to Streptozotocin-based Chemotherapy in Pancreatic Neuroendocrine Tumours
Introduction: Streptozotocin (STZ) is an alkylating agent inducing DNA damage mainly repaired by MGMT. STZ-based chemotherapy is the first line treatment of non-resectable well-differentiated PNET. As for temozolomide, tumour MGMT deficiency may predict the efficacy of STZ in PNET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Olivia Hentic
Authors: Hentic O, Cros J, Zappa M, Rebours V, ...
Keywords: MGMT, Streptozotocin, PFS
#1734 Efficacy of Lanreotide (LAN), Both Alone and in Combination with Targeted Therapies in a Preclinical Model of Pancreatic Neuroendocrine Tumors (pNETs)
Introduction: CLARINET trial has proven the antiproliferative effects of LAN in patients with non-functioning gastro-entero-pNETs. However, the combination of LAN with targeted therapies is widely used in clinical practice and should be further evaluated.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: PhD Oriol Casanovas
Keywords: Lanreotide, pNET
#1828 5-Fluorouracile Plus Dacarbazine in Metastatic Digestive Neuroendoendocrine Tumors: Efficacy and Potential Biomarkers
Introduction: The 5-fluorouracile (5FU) + dacarbazine (DTIC) combination has been poorly evaluated in NET
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Dr Louis de Mestier
#1900 Well-Differentiated G1/G2 Pancreatic NETs Can Evolve Towards G3 Tumors
Introduction: Well-differentiated G1/G2 pancreatic NET (pNET) may evolve towards well-differentiated G3 pNET or carcinoma (pNEC)
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Muller Nelly
Authors: Hentic O, Cros J, Rebours V, Zappa M, ...
#1901 Portal Hypertension-Related Digestive Hemorrhage in Patients with Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (pNET) can cause portal hypertension (PHT)
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Nelly Muller
#2248 High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?
Introduction: Grade 3 (G3) neuroendocrine neoplasms (NEN), arising from the gastro-entero-pancreatic system (GEP), are classified according to WHO 2010 and defined as having a Ki67 of > 20%. However this groups together G3 well differentiated neuroendocrine tumours (WD-NET) with poorly differentiated neuroendocrine carcinomas (PD-NEC). Recently, WHO have proposed a new classification for pancreatic NEN, with sub-division into G3 WD-NET and G3 PD-NEC
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Dr Dalvinder Mandair
Authors: Furnace M, Muller G, Rundell C, Shah R, ...
#2271 Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture
Introduction: Symptom control in functioning neuroendocrine tumors(NETs) may be difficult in some cases, thus, new therapeutic options, including multi-receptor targeting drugs are required.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Aura Dulcinea Herrera-Martínez